Business
Eco Petroleum-ECPO Completes Acquisition of Immunotherapy Drug Development Company
Eco Petroleum-ECPO Completes Acquisition of Immunotherapy Drug Development Company.
About this update from Enzolytics Inc.
[{"type":"text","content":"\n \n \n Eco Petroleum-ECPO Completes Acquisition of Immunotherapy Drug Development Company\n \n \nEco Petroleum-ECPO Completes Acquisition of Immunotherapy Drug Development Company\n \n MONROVIA, CA--(Marketwired - Jun 14, 2017) - Eco Petroleum Solutions, Inc. (OTC PINK: ECPO) announces that it has completed the acquisition of Immunotech Laboratories, Inc. (OTC PINK: IMMB), a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases, in a share exchange transaction. Immunotech is committed to creating drugs for the better health of mankind and the realization of shareholder value for the existing shareholder groups of the two entities.\n Immunotech's flagship compound ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.\n The US Patented ITV-1 treatment has successfully completed Phase I, II and III clinical testing in Sophia, Bulgaria through Immunotech Laboratories BG - Europe LTD, a subsidiary of the acquired entity. The Phase III testing was conducted at the National Center of Infectious and Parasitic Diseases in Sophia, Bulgaria (www.ncipd.org) on a test group of salvage patients suffering from HIV/AIDS using the best modern methods as approved at the latest World Practice Conference. The final report issued by the Ministry of Health demonstrated improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK and of the index CD4/CD8, decrease in the viral load, a good treatment effect on opportunistic infections, compatibility with all of the other modern antiretroviral drugs, and exceptional tolerance in all patients with a complete lack of any major side effects. Approximately eighty percent of the test subjects reported viral loads at a nil level as a result of the treatment. The final report of the clinical trial is available on our website: www.immunotechlab.com\n Phase IV, the application for a permit for mass use in the European Union has been completed and submitted. The validation of manufacturing of the treatment produced by a US contract ma...